Our focus lies on the development and commercialization of enzymes for the innovative and sustainable production of API intermediates, fine and commodity chemicals, and compounds applied in consumer goods. We aim to contribute to a greener and safer environment by supporting our customers in applying enzymes in their manufacturing processes.
For this, we assembled an international team of scientists with longstanding expertise in enzyme engineering, synthetic chemistry, bioinformatics, molecular biology, and process development. This comprehensive knowledge allows us to provide one stop solutions, guiding our customers through the entire development process, starting from the idea, all the way to the commercialization on a hundred to a thousand-ton scale.
Enzymaster (Ningbo) Bio-Engineering Co., Ltd. was founded as a Sino-foreign joint venture in Ningbo (China) in 2013. Here, at Enzymaster’s headquarters, the company has already gained approximately 237 employees. Located just south of Shanghai, Ningbo and its surrounding area provides a broad network of academic and industrial collaboration partners from the biotechnology and chemical sector.
The international business unit located in Düsseldorf (Germany) represents your partner in the international market, serving mainly the European and North American markets. Here, we take care of the international marketing of our branded technology and product offers and accompany our customers through all project phases.
Zhenlin Lv is responsible for the executive management and operation of Enzymaster, implementing the strategic plans of the company. He is rich in experience in business management, with an in-depth understanding and many insights on the chemical and pharmaceutical industries.
Dr. Thomas Daussmann is responsible for the management and marketing of Enzymaster products and services on the international market. He is a biocatalysis expert, with more than 20 years of enzyme-related entrepreneurial, R&D and sales experience.
Dr. Haibin Chen is responsible for the oversight of R&D projects, technology development and IP strategy. He has extensive scientific experience in the biomedical industry with specific focus on protein engineering and state-of-the-art technology for biocatalysis.
Mr. Li received his MBA from Babson College and MS in Chemistry from the City University of New York. He currently holds the position of Founding Partner of YuanBio Venture Capital, Chairman of Sunforest Capital and Managing Partner of Yuanming Capital. Mr. Li has over 20 years of experience in pharmaceutical R&D, manufacturing, management, and investment.
Dr. Xu graduated from Peking University. From July 2014 to present he served as the General Manager of the Healthcare Investment Department at Shenzhen Fortune Venture Capital Co. Ltd. Dr. Xu possesses rich investment experience in medical health care area.
Mr. Su has worked for 8 years at PwC Zhongtian Certified Public Accountants and Citi Orient Securities. Holds qualifications as a Certified Public Accountant and the Sponsor reprent. Possesses professional knowledge and extensive experience in the securities market, familiar with the listing process and market regulatory system. Currently serves as a founding partner of Kangjun Investment Management (Beijing) Co., Ltd, with rich practical experience and capabilities in investment and financing.
Prof. Dr. Dörte Rother has been with the Institute of Bio- and Geosciences – Biotechnology (IBG-1) at Forschungszentrum Jülich since 2009 and has been a member of the institute’s directorate since March 2025. She leads the Biocatalysis research group and, following the Jülich model, simultaneously holds a professorship at the Chair of Biocatalysis at RWTH Aachen University.
In 2012, she established her own Helmholtz Young Investigators Group in Jülich, which has been additionally supported by an ERC Starting Grant since 2017. In 2018, she was appointed Full Professor for Synthetic Enzyme Cascades at RWTH Aachen University and continues to head the Biocatalysis group at Forschungszentrum Jülich.
Her outstanding contributions to multi-step biocatalysis and sustainable process development have been recognized with the DECHEMA Prize (2018) and the Biotrans Junior Award (2019).
Dr. David Rozzell received his Ph.D. in Chemistry at the Harvard University. He is a bio-enzyme industry expert, worked formerly at BioCatalytics, founder of Sustainable Chemistry Solutions, Inc. and currently Senior VP at Provivi, Inc. Dr. Rozzell is committed to the biotechnology industry and to applying enzymes more efficiently. He has extensive experience in technology and operations and founded and operated a company that produced new enzymes.
Dr. Rainhard Koch studied microbiology in Göttingen and worked as research scientist at the Bayer AG for 28 years. He established and led Bayer‘s enzyme technology department and developed several enzyme based textile and paper auxiliaries. During the last years he worked as principle expert for biocatalysis in Bayer‘s biocatalysis team. He was responsible for several large collaborations with academic and industrial partners.
In further functions he lead the biomaterials platform at Bayer Crop Science and developed biodegradable polymers. Rainhard Koch is mentioned as inventor on 42 patents and author of more than 20 scientific publications.
